Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mammary Neoplasm, Human”

678 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 678 results

Testing effectiveness (Phase 2)Looking for participantsNCT05983107
What this trial is testing

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Who this might be right for
HR+/HER2- Advanced Breast CancerTargeted Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102
Testing effectiveness (Phase 2)Active Not RecruitingNCT05262400
What this trial is testing

Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Who this might be right for
Breast CancerSolid Tumors
Pfizer 235
Testing effectiveness (Phase 2)Study completedNCT01885013
What this trial is testing

Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 126
Testing effectiveness (Phase 2)UnknownNCT06470672
What this trial is testing

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
Fudan University 32
Early research (Phase 1)Active Not RecruitingNCT04521686
What this trial is testing

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Who this might be right for
CholangiocarcinomaChondrosarcomaGlioma+1 more
Eli Lilly and Company 200
Early research (Phase 1)Study completedNCT05585034
What this trial is testing

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal MelanomaNon-small Cell Lung Cancer, Squamous or Non-squamous+6 more
Xencor, Inc. 60
Early research (Phase 1)Study completedNCT04504669
What this trial is testing

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Who this might be right for
Clear Cell Renal Cell CancerNon-Small-Cell Lung CancerTriple Negative Breast Neoplasms+6 more
AstraZeneca 60
Early research (Phase 1)WithdrawnNCT07150767
What this trial is testing

A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer

Who this might be right for
Locally Advanced Breast Cancer (LABC)
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Early research (Phase 1)Study completedNCT01526473
What this trial is testing

A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901

Who this might be right for
HER2+ Cancer
H. Kim Lyerly 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT05593094
What this trial is testing

Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsHER2-positive Breast Cancer
Hoffmann-La Roche 210
Early research (Phase 1)Ended earlyNCT02964507
What this trial is testing

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Who this might be right for
Neoplasms
GlaxoSmithKline 124
Large-scale testing (Phase 3)Study completedNCT03084939
What this trial is testing

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 351
Large-scale testing (Phase 3)Study completedNCT01702571
What this trial is testing

Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Who this might be right for
Breast Cancer
Hoffmann-La Roche 2,185
Early research (Phase 1)Looking for participantsNCT06400472
What this trial is testing

Sofe-M in Participants With Selected Advanced Solid Tumors

Who this might be right for
Ovarian NeoplasmsEndometrial NeoplasmsUterine Cervical Neoplasms+4 more
Eli Lilly and Company 575
Not applicableLooking for participantsNCT06106477
What this trial is testing

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Medical College of Wisconsin 20
Testing effectiveness (Phase 2)Ended earlyNCT03894007
What this trial is testing

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

Who this might be right for
Early-stage Breast CancerHER2-positive Breast Cancer
Renske Altena 6
Testing effectiveness (Phase 2)Looking for participantsNCT06827236
What this trial is testing

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Who this might be right for
Locally Advanced Breast CancerUnresectable Breast CarcinomaMetastatic Breast Cancer
BioNTech SE 380
Testing effectiveness (Phase 2)Ended earlyNCT01394211
What this trial is testing

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastMale Breast Cancer+4 more
University of Arizona 2
Early research (Phase 1)UnknownNCT03552406
What this trial is testing

Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
ISU Abxis Co., Ltd. 33
Early research (Phase 1)Ended earlyNCT02628535
What this trial is testing

Safety Study of MGD009 in B7-H3-expressing Tumors

Who this might be right for
MesotheliomaBladder CancerMelanoma+10 more
MacroGenics 67
Next Page